Market Size & Trends
The Asia Pacific oncology based molecular diagnostics market size was estimated at USD 822.5 million in 2024 and is projected to reach USD 1,560.75 million by 2033, growing at a CAGR of 6.8% from 2025 to 2033. Rising cancer burden across breast, prostate, and colon, along with the aging population, is driving the demand for effective diagnostic solutions in the region. Advancements in technology, the growing adoption of point-of-care testing (POCT), and developments in biomarker identification systems are supporting market expansion. In addition, government initiatives aimed at cancer screening and early detection, as well as increased healthcare investments across emerging economies, are contributing to the rising demand for molecular diagnostics.
The increasing requirement for accurate and rapid testing methods and the growing integration of Next-Generation Sequencing (NGS) techniques for oncology diagnostics further support the market. Awareness of personalized medicine and the adoption of targeted treatment strategies are also influencing market trends. Expanding research and development efforts and collaborations to develop innovative molecular diagnostic solutions are expected to strengthen the regional market outlook through 2033.
Growing healthcare infrastructure, particularly in countries like China, India, and Japan, is boosting the accessibility and adoption of advanced diagnostic technologies. Rising partnerships between diagnostic laboratories and healthcare institutions and the focus on early cancer detection programs are fostering regional growth. Furthermore, the increasing shift toward non-invasive testing methods, such as liquid biopsies, and the availability of advanced genetic testing platforms are expected to create significant opportunities for the market in the coming years.
Overall, the Asia Pacific market is evolving with innovations like liquid biopsies, advanced NGS platforms, AI-driven analytics, and portable molecular testing devices that make cancer detection faster and more accurate. Introducing multi-omics approaches and strategic collaborations further supports personalized treatment and early detection initiatives. However, factors such as high costs of advanced technologies, uneven access across rural areas, and regulatory complexities may influence the pace of widespread adoption in the region.
Market Concentration & Characteristics
Innovation is high in the Asia Pacific oncology based molecular diagnostics industry, focusing on early detection, personalized treatment, and non-invasive diagnostic approaches. Advancements in next-generation sequencing (NGS), digital PCR, and AI-powered data analysis improve diagnostic precision and turnaround times. Technologies such as liquid biopsy, RNA sequencing, and tumor mutation burden profiling are gaining traction across various cancer types. Integrating molecular diagnostics with digital health platforms and clinical decision support tools further enhances real-time clinical applicability.
M&A activity in the region is moderate, with larger diagnostics and life sciences companies acquiring smaller firms specializing in bioinformatics, liquid biopsy, and tumor profiling. Collaborations between diagnostic developers and pharmaceutical companies are increasing, particularly for companion diagnostics that support targeted therapies. These strategic deals aim to broaden testing capabilities, strengthen oncology-focused portfolios, and accelerate regulatory and geographic expansion across Asia Pacific.
Regulatory frameworks across countries like Japan, China, and Australia are becoming more structured, with stringent requirements for analytical performance and clinical validation of oncology diagnostics. While approval processes can be complex, government initiatives and faster regulatory pathways for innovative tests, including liquid biopsies and companion diagnostics, support market growth. Emphasis on clinical utility and real-world evidence remains key for regulatory approvals in this sector. Product expansion is robust, with companies introducing tumor-specific genomic panels, multi-gene testing solutions, and companion diagnostics tailored for cancer therapies. Innovations in liquid biopsy platforms and minimal residual disease (MRD) monitoring tools are also advancing. Automation of testing workflows, improved turnaround times, and integration with electronic health records (EHRs) enhance operational efficiency for laboratories and hospital-based diagnostic facilities.
Regional expansion is active across high-growth markets such as China, India, and Southeast Asia, supported by partnerships with local diagnostic laboratories, research institutes, and healthcare providers. Rising healthcare expenditure, cancer screening programs, and increasing adoption of precision oncology are creating opportunities for broader test availability. While developed markets like Japan lead in adoption, emerging economies in the region are witnessing accelerated uptake due to improved healthcare infrastructure and awareness campaigns.
Access Research Report@ https://www.grandviewresearch.com/industry-analysis/asia-pacific-oncology-based-molecular-diagnostics-market-report
Key Asia Pacific Oncology Based Molecular Diagnostics Company Insights
Key participants in the Asia Pacific oncology-based molecular diagnostics market focus on strategies such as expanding their test portfolios, collaborating with hospitals and cancer research centers, and investing in advanced technologies like next-generation sequencing (NGS) and liquid biopsy. These initiatives aim to improve diagnostic accuracy, enhance access to personalized oncology testing, and align with evolving clinical practices.
Key Asia Pacific Oncology Based Molecular Diagnostics Companies:
- Abbott
- Agilent Technologies, Inc
- bioMerieux SA
- Danaher
- Hoffmann-La Roche Ltd.
- Illumina
- Novartis AG
- QIAGEN
- Siemens Healthineers AG
- TBG Diagnostics Limited
- Thermo Fisher Scientific Inc
- Sysmex
Recent Developments
- In May 2025, researchers at the Indian Institute of Technology, Indore (IIT-I), unveiled a Quantum AI-based sequencing technology. This innovation combines explainable AI with solid-state nanopore sequencing to enable rapid and accurate detection of genetic mutations, potentially surpassing traditional NGS in speed and cost-efficiency. Offering high-resolution genomic insights, this development is expected to advance the future of molecular diagnostic tools in India, supporting precision oncology and personalized treatment approaches.
- In April 2025, Promega’s ProDx MSI Detection Kit received an innovative medical device registration certificate from China’s National Medical Products Administration (NMPA). This PCR-based assay detects microsatellite instability (MSI) in colorectal cancer tissue, facilitating the identification of patients who may require further genetic testing for Lynch syndrome. This milestone enhances the accessibility of advanced molecular diagnostics in China’s clinical laboratories, strengthening the adoption of precision oncology solutions in the region.
- In September 2023, Agilent Technologies, Inc., signed a research collaboration agreement with the National Cancer Centre Singapore (NCCS) to advance translational cancer research focused on the genomic landscape of cancers prevalent in Asia. This initiative uses Agilent’s automated NGS platforms and multi-gene sequencing assays at the Cancer Discovery Hub in Singapore to enable precise molecular profiling and support the development of personalized cancer diagnostics.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment